ALT - Altimmune Net earnings per share (EPS TTM)

Altimmune, Inc. (ALT) is actively developing pemvidutide, offering an effective solution for weight loss while preserving muscle mass. The company leverages its own peptide ecosystem to create a unique therapeutic circuit. On GURU.Markets, the company's rolling annual per-share profit confirms the quality of the business, with the indicator value standing at -0.79. Stability of development is ensured by precise pharmaceutical logistics, guaranteeing the safety of all clinical trials.

ALT (Altimmune, Inc.) Earnings per share for the last twelve months history from 07/04/2022 to 11/12/2026

Altimmune Inc - analytical breakdowns and key metrics (ALT)

- share price and expert price forecast:

Stock Quotes Altimmune, Inc.|ALT - Analyst Forecast Prices

- market capitalization statistics:

Market Capitalization Altimmune, Inc.|ALT - Enterprise Value

- business book valuation details:

Book Value per Share Altimmune|ALT - Company Book Value|Market Value to Book Value Ratio altimmune.com|ALT - Company Assets

- debt level and financial liquidity data:

- net income and valuation multiples indicators:

ALT - Net Profit|Expected Profit Altimmune, Inc.|ALT - Price to Earnings Ratio|Projected Price to Earnings Altimmune|ALT - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Altimmune, Inc.|ALT - Operating income before deduction of amortization|Earnings per share for the last twelve months Altimmune|ALT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months altimmune.com|ALT - Net earnings per share growth this year|Expected earnings per share growth for next year Altimmune, Inc.

Fundamental company analysis:ALT - Altimmune, Inc.

Net income per share over 12 months determines the real return on each unit of capital, allowing for an assessment of the business's internal resilience to market volatility. For the R&D-intensive Altimmune, Inc. (ALT), which invests in peptide development and a costly staff of endocrinologists, the rolling annual earnings per share verifies the efficiency of clinical trial cost management relative to the volume of issuance.

Competitors of Altimmune, Inc.